GO
| HSI1 | 23,350.03 | +295.00 | 304.95B |
| HSCEI1 | 7,699.76 | +87.28 | 86.75B |
| Back Zoom + Zoom - Block Traded | |
|
2026-07-03 11:31:49 UBS published a report stating that it hosted a healthcare virtual roadshow meeting for WUXI BIO (02269.HK). Management reiterated its guidance for 2026 revenue growth of 13% to 17% YoY (16% to 20% excluding foreign exchange impact). Despite ongoing foreign exchange pressure, this reflects management's confidence in underlying demand and operational execution. Following strong performance from January to April, new order momentum remained healthy from May to June, with continued growth in the European and US markets, while the China market also showed a solid recovery trend. New technology platforms, particularly bispecific antibodies, continued to be key growth drivers. UBS noted that WUXI BIO's pricing trend is becoming more favorable, with new contract prices increasing by 5% to 15%, above the historical increase range of 3% to 5% in previous years. Higher-priced orders signed earlier this year will help support revenue growth next year and underpin the company's target of a 20% revenue CAGR over the next three years, with the manufacturing business expected to grow by 30%. Regarding capacity expansion, management disclosed that capacity utilization in China may approach full capacity next year, while capacity construction overseas, including Singapore and Ireland, is also progressing smoothly. Based on its optimistic three-year outlook, UBS raised its revenue forecasts for WUXI BIO for fiscal years 2027 to 2029. As a result, it lifted its discounted cash flow (DCF)-based TP from HKD49.3 to HKD51.1 and reiterated its Buy rating. (ad/da)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |